An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update)

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 12, 2008, Pages 2181-2195

  Philis Tsimikas, Athena ^a  

^a Whittier Institute for Diabetes   (United States)

Author keywords

Basal insulin; Basal oral therapy; Hypoglycemia; Insulin detemir; Type 2 diabetes; Weight

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

ADD ON THERAPY; BEDTIME DOSAGE; BOLUS INJECTION; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BINDING; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN;

EID: 50949118339     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.12.2181     Document Type: Review

References (46)

1. Home, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacotficr 2006;7:325-43
2. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analogue of human insulin. Pharm Res 2004;21(8):1498-504
3. Kurtzhals P. How to achieve a predictable basal insulin? Diabetes Metab 2005;31(4-C2):25-33
4. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20
5. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins, An assessment of the basal analogues based on isoglycemic clamp studies. Diabetes Obes Metab 2007;9:648-59
6. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28(5):1107-12
7. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9(3):290-9
8. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6
9. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005;7:73-82
10. Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004;6:579-88
11. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850-7
12. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7
13. Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-36
14. Hermansen K, Fontaine P, Kukolja K, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9
15. Kølendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 2006;237:729-35
16. Robertson KJ, Schoenle E, Gucev Z, et al. Insulin detemir compared with NPH insulin in children and adolescents with T1DM. Diabet Med 2007;24(1):27-34
17. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safity of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008;25:442-9
18. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007;24(6):635-42
19. Le Floch J-P, Eschwege E, Levy M, et al. and the ADAPT Study Group. Interim results of a French multi-centre trial comparing insulin detemir once-daily versus twice-daily in people with type 1 diabetes: the ADAPT™ study. Diabet Med 2006;23(Suppl 4):335 (P927)
20. Dornhorst A, Lüddeke HJ, Sreman S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007;61:523-8
21. Lüddeke HJ, Sreenan S, Aczel S, et al.; PREDICTIVE Study Group. PREDICTIVE™ - a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007;9:428-34
22. Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418-27
23. Trippe B, Honka M, Kozlovski P, Dornhorst A. Initiating insulin detemir improves glycemic control without weight gain in OAD-treated insulin naive patients with type 2 diabetes: 6 month data from PREDICTIVE™. Diabetes 2007;56(Suppl 1):A570 (2248-PO)
24. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812
25. Rašlová K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66(2):193-201. Corrigendum: Diabetes Res Clin Pract 2006;72:112
26. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64
27. Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients - the PREDICTIVE™ BMI clinical trial. Diabet Med 2008; doi: 10.1111/j.14645491.2008.02483.x
28. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74
29. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
30. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
31. Rosenstock J, Davies M, Home P, et al. A randomised, 52-week, treat-to-target trial comparing insuln detemir with insulin glargine when added to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-26
32. Meneghini L, Koenen C, Weng W, Selam J-L. The usage of a simplified self-titration dosing guideline (303 Algorithm) f6r insulin detemir in patients with type 2 diabetes - results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab 2007;9:902-13
33. Dornhorst A, Lüddeke HJ, Koenen C, et al.; PREDICTIVE™ Study Group. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE™. Diabetes Obes Metab 2008;10:75-81
34. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophanc insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;2:CD005613
35. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5
36. Ridderstrale M, Gudbjarnsdottir S, Eliasson B, et al.; Steering Committee of the Swedish National Diabetes Register (NDR). Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 2006;259(3):314-22
37. Rašlová K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Invest 2007;27:279-85
38. Philis-Tsimikas A, Koenen C, Pedersen CB, Thorsteinsson B. Use of insulin detemir once-daily results in less weight gain compared with the use of NPH insulin, particularly in obese subjects with type 2 diabetes. Diabetologia 2007;50(Suppl 1):S404
39. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007;9:209-17
40. Saudek CD. Novel forms of insulin delivery. Endocrinol Metab Clin North Am 1997;26:599-610
41. Hordern SVM, Wright JE, Umpleby AM, et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005;48(6):420-6
42. Hennige AM, Sartorius T, Tschritter O, et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006;49(6):1274-82
43. Tschritter O, Hennige AM, Preissl H, et al. Cerebrocortical beta activity in overweight humans responds to insulin detemir. PLoS One 2007;2(11):e1196
44. EMEA labelling for insulin detemir. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/levemir/H-528-PI-en.pdf [Accessed 24 January 2008]
45. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
46. De Vries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007;23:441-54